Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide and Anastrozole for Testotoxicosis (BATT)
NCT00094328Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Primary completion
- May 2008
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 2, open-label trial of bicalutamide and anastrozole in Familial male-limited precocious puberty (FMPP), sponsored by AstraZeneca. Primary endpoints: Change in Growth Rate (cm/Year) at 12 months and Change in Growth Rate (SD Units) at 12 months. Started Nov 2004; status: completed.
02
Drugs
bicalutamideanastrozole
03
Conditions
Familial male-limited precocious puberty (FMPP)
Beyond the preview
Go deeper on NCT00094328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094328.